Advancing the Future of
Antiviral Therapeutics
Our proprietary drug discovery platform is designed to target essential viral replication mechanisms, accelerating the development of next-generation antivirals against emerging and persistent viral threats.
Our Scientific Mission
At Avin Therapeutics, we integrate medicinal chemistry, virology, and computational biology to develop next-generation antiviral therapeutics that target viral replication, focusing on emerging viral threats and unmet medical needs worldwide.
The Science Behind Our Approach
Innovative Technology Platform
Our proprietary platform leverages advanced molecular insights to identify and target conserved viral mechanisms, enabling the development of therapeutics with broad-spectrum potential.
Broad-Spectrum Efficacy
Developing next-generation therapeutics targeting conserved viral replication mechanisms to combat multiple viral families and emerging threats.
Precision Targeting
Leveraging structure-based drug design and medicinal chemistry to selectively inhibit essential viral targets.
Our Therapeutic Strategy
At Avin Therapeutics, we focus on developing direct-acting antivirals targeting essential viral replication mechanisms, with an emphasis on broad-spectrum activity, precision, and overcoming drug resistance.
Direct Acting Antivirals
Developing potent small-molecule therapeutics that directly inhibit essential viral enzymes and replication processes.
Broad-Spectrum Antiviral Approach
Targeting conserved viral mechanisms to develop therapeutics with activity against multiple viruses and viral families.
Rapid Response to Emerging Threats
Leveraging medicinal chemistry and structure-based drug design to accelerate antiviral discovery against emerging and re-emerging viruses.
Advantages of Our Approach
Our platform technology offers significant advantages over traditional antiviral development strategies.
Traditional Approaches
Avin Therapeutics Platform
🌐 Global Health Impact
At Avin Therapeutics, we aim to transform global health through innovative, broad-spectrum and long-acting antiviral therapies, focusing on three key therapeutic areas:
Arboviral Infections
Developing broad-spectrum antivirals against dengue, Zika, chikungunya, and other emerging mosquito-borne viral threats.
Respiratory Viral Infections
Advancing next-generation therapeutics targeting influenza, RSV, coronaviruses, and other respiratory viruses.
HIV & Hepatitis B (HBV)
Developing long-acting antiviral therapies to improve treatment outcomes, reduce dosing frequency, and enhance patient adherence.
Our mission is to address unmet medical needs, combat emerging viral threats, and expand access to effective antiviral treatments worldwide.